Drug intelligence / Profile preview

[18F]myo-1

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

[18F]myo-1 is one of eight new [18F]fluoro-inositol-based radiotracers developed for Positron Emission Tomography (PET) imaging. It is designed with a myo-inositol configuration and features a propyl linker bearing fluorine-18. The fluorinated arm can be attached to either a hydroxyl group (O-alkylated inositols) or the cyclohexyl backbone (C-branched derivatives). These inositols are synthesized in acetylated or hydroxylated forms to modulate lipophilicity. [18F]myo-1 is intended for use as a PET imaging agent, particularly in the context of breast cancer detection and monitoring.

Beyond the preview

Go deeper on [18F]myo-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]myo-1.

Explore the full profile